News | February 22, 2022
Infinity Holding Group to acquire 43.7 per cent stake in Jagsonpal Pharma
The transaction as well as the open offer is expected to be completed by June this year.
The transaction as well as the open offer is expected to be completed by June this year.
The sale is expected to close in the first quarter of 2022
According to the Indian Journal of Medical Research in 2018, the estimated prevalence of pre-diabetes in India is 14%, which means that one out of six Indians is pre-diabetic
The company will now be allowed to sell its proprietary and validated tinctures, gummies, and capsules across the UK
Fitch estimates JPL's EBITDA to drop significantly in FY23 due to lower volume and narrowing of the margin to 11% (FY22 estimate: 14%).
The company registered consolidated total revenue of Rs 590.70 crore for Q3FY22.
The newly enhanced drug development platform will help empower innovators with the fastest development timelines
Resolv ER may remedy leading causes of blindness in adults
BDR Pharmaceuticals is a home-grown company with operations in India and overseas. It’s known for its formulations portfolio and has a presence in specialty medicines. The company has ambitious plans as it has ramped up capacity and looking to foray into regulated markets. Raheel Shah, Director, BDR Group of Companies shares his insights in an interview with Thomas C Thottathil, Editor, Indian Pharma Post
The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad
Subscribe To Our Newsletter & Stay Updated
